1. Home
  2. LCTX vs TG Comparison

LCTX vs TG Comparison

Compare LCTX & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.69

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Logo Tredegar Corporation

TG

Tredegar Corporation

HOLD

Current Price

$7.49

Market Cap

301.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCTX
TG
Founded
1990
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
407.7M
301.0M
IPO Year
N/A
1989

Fundamental Metrics

Financial Performance
Metric
LCTX
TG
Price
$1.69
$7.49
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$4.25
N/A
AVG Volume (30 Days)
1.3M
162.7K
Earning Date
11-06-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,816,000.00
$691,173,000.00
Revenue This Year
$5.24
N/A
Revenue Next Year
$126.78
N/A
P/E Ratio
N/A
$115.64
Revenue Growth
24.05
43.30
52 Week Low
$0.37
$6.25
52 Week High
$2.09
$9.43

Technical Indicators

Market Signals
Indicator
LCTX
TG
Relative Strength Index (RSI) 46.72 44.86
Support Level $1.65 $7.42
Resistance Level $1.82 $7.63
Average True Range (ATR) 0.08 0.26
MACD 0.00 -0.04
Stochastic Oscillator 48.00 12.18

Price Performance

Historical Comparison
LCTX
TG

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About TG Tredegar Corporation

Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.

Share on Social Networks: